• 1
    Rutherford S., Montoro M., McGhee W., Strong T.. Thromboembolic disease associated with pregnancy: an 11-year review. Am J Obstet Gynecol 1991;164: (2 Pt 2):286.
  • 2
    National Institutes of Health Consensus Development ConferencePrevention of venous thrombosis and pulmonary embolism. JAMA 1986;256: 744749.
  • 3
    Lane D.A., Mannucci P.M., Bauer K.A., et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996;76: 824834.
  • 4
    Ginsberg J.S., Hirsh J.. Use of antithrombotic agents during pregnancy. Fifth American College of Chest Physicians (ACCP) on Antithrombotic Therapy. Chest 1998;114(Suppl):52455305.
  • 5
    Ginsberg J.S., Hirsh J., Turner D.C., Levine M.N., Burrows R.. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61: 197203.
  • 6
    Ginsberg J.S., Kowalchuk G., Hirsh J., Brill-Edwards P., Burrows R.. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med 1989;149: 22332236.
  • 7
    Hirsh J., Warkentin T.E., Raschke R., Granger C., Magnus Ohman E., Dalen J.E.. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114: 48955105.
  • 8
    Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332: 13301335.
  • 9
    Monreal M., Lafoz E., Olive A., Del R.L., Vedia C.. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications for coumarin. Thromb Haemost 1994;71: 711.
  • 10
    Forestier F., Daffos F., Capella-Pavlovsky M.. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984;34: 557560.
  • 11
    Omri A., Delaloye J.F., Anderson H., Bachman F.. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989;61: 5556.
  • 12
    Sanson B-J., Lensing A.W.A., Prins M.H., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81: 668672.
  • 13
    Ellison J., Walker I.D., Greer I.A.. Antenatal use of enoxaparin for prevention and treatment of thromboembolism during pregnancy. Br J Obstet Gynaecol 2000;107: 11161121.
  • 14
    EUROCAT Working Group. EUROCAT Report 7. 15 years of surveillance of congenital anomalies in Europe 1994;1980: 1997.
  • 15
    Mamelle N., Munoz F., Grandjean H.. Fetal growth from the AUDIPOG study. I. Establishment of reference curves. J Gynecol Obstet Biol Reprod 1996;25: 6170.
  • 16
    Blondel B., Breart G., du Mazaubrun C., et al. The perinatal situation in France. Trends between 1981 and 1995. J Gynecol Obstet Biol Reprod 1997;26: 770780.
  • 17
    Kupferminc M.J., Eldor A., Steinman N., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340: 913.
  • 18
    Dahlman T.C.. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993;168: 12651270.
  • 19
    US Department of Health and Human Services. Food and Drug Administration, Washington DC. Guidance for Industry. Establishing Pregnancy Registries (Draft Guidance). June, 1999.
  • 20
    Volpe J.J.. Intracranial hemorrhage: germinal matrix-intraventricular hemorrhage of the premature infant. In: VolpeJ.J., Neurology of the Newborn. Philadelphia : WB Saunders, 1995: 403463.
  • 21
    US Department of Health and Human Services. Food and Drug Administration. Reviewer Guidance. Evaluation of Human Pregnancy Outcome Data (Draft Guidance). June, 1999.
  • 22
    Koren G., Pastuszack A., Ito S.. Drugs in pregnancy. N Engl J Med 1998;338: 11281137.
  • 23
    Nelson-Piercy C., Letsky E.A., de Swiet M.. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176: 10621068.
  • 24
    Dulitzki M., Pauzner R., Langevitz P., Pras M., Many A., Schiff E.. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996;87: 380383.
  • 25
    Gibson J.L., Ekevall K., Walker I., Greer I.A.. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. Br J Obstet Gynaecol 1998;105: 795797.
  • 26
    Brennand J.E., Walker I.D., Greer I.A.. Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin. Acta Haematol 1999;101: 5355.